Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Edesa Biotech Inc (EDSA)

Edesa Biotech Inc (EDSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors GlobeNewswire - Thu Jun 11, 8:15AM CDT

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics...

EDSA : 7.31 (+0.14%)
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury GlobeNewswire - Fri Jun 5, 8:20AM CDT

Analyses demonstrate consistent positive signals across endpoints in AKI patients Findings derived from post hoc analysis of 101 patients also experiencing respiratory distress New data and analysis...

EDSA : 7.31 (+0.14%)
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference GlobeNewswire - Tue May 19, 8:15AM CDT

Oral presentation at ERA Congress, the flagship European nephrology meeting Company expects to present additional data TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:...

EDSA : 7.31 (+0.14%)
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results GlobeNewswire - Thu May 14, 3:30PM CDT

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases,...

EDSA : 7.31 (+0.14%)
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit GlobeNewswire - Tue Mar 31, 3:20PM CDT

TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases,...

EDSA : 7.31 (+0.14%)
Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment GlobeNewswire - Thu Mar 26, 8:15AM CDT

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases,...

EDSA : 7.31 (+0.14%)
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study GlobeNewswire - Tue Feb 24, 8:15AM CST

Results in a population of 278 patients affirm statistically significant mortality reductions Benefits observed across severity groups and in subjects with serious comorbidities Company files provisional...

EDSA : 7.31 (+0.14%)
Edesa Biotech Reports Fiscal 1st Quarter 2026 Results GlobeNewswire - Fri Feb 13, 3:20PM CST

TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases,...

EDSA : 7.31 (+0.14%)
Edesa Biotech Reports Fiscal Year 2025 Results GlobeNewswire - Fri Dec 12, 2025

TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases,...

EDSA : 7.31 (+0.14%)
Interest Rate Decisions Due on Both Sides of Border Next Week Baystreet - Mon Dec 8, 2025

Monday U.S. Featured Earnings Oracle Corp. (NYSE:ORCL) (Q2) EPS for $1.29, compared ...

YEXT : 4.99 (-2.73%)
AVGO : 391.50 (+5.59%)
JOUT : 43.14 (-0.71%)
ORCL : 139.31 (-1.62%)
EDSA : 7.31 (+0.14%)
TOL : 146.42 (-3.44%)
CIEN : 435.27 (+3.91%)
COST : 954.62 (+0.75%)
FERG : 222.03 (-0.52%)
AZO : 3,071.02 (-0.12%)
ADBE : 221.09 (-0.20%)
SNPS : 433.22 (-0.78%)

Barchart Exclusives

Alibaba Shares Are Gaining on AI Optimism. Here's What to Know. Barchart - 8 minutes ago
Alibaba stock is rallying as its pre-earnings briefing signals AI momentum and improving core business efficiency. But should you load up on BABA shares into strength today? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.